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ABSTRACT
BACKGROUND AND OBJECTIVES: Temporomandibular 
disorders (TMD) involve a set of craniofacial changes, which may 
involve temporomandibular joint (TMJ), jaw muscles and/or as-
sociated structures. Muscle TMD is the most frequent, and one of 
its subtypes is myofascial pain. Botulinum toxin type A (BoNT A), 
has been studied to control pain, including myofascial pain, and is 
related to pain relief mechanisms not only in neuromuscular junc-
tion receptors. This study aimed at evaluating articles addressing 
BoNT A to treat jaw muscles myofascial pain.
CONTENTS: Pubmed, LILACS and BVS databases were queried 
from 2000 to April 2012, crossing the following keywords: botu-
linum toxin type A, myofascial pain syndromes, facial pain, tem-
poromandibular joint disorder syndrome, trigger-points, bruxism, 
temporomandibular joint, masseter muscle and temporalis muscle. 
Inclusion criteria were randomized double blind or blind studies, 
with 10 or more participants, with randomized methodological as-
pects, relating the use of botulinum toxin for jaw muscles TMD 
myofascial pain, more specifically masseter and temporalis mus-
cles, and limited to the English language. Six articles were found 
and included in this study. 
CONCLUSION: BoNT A was not more effective to treat myofas-
cial pain than established conventional treatments. Because there 
are many uncontrolled variables in the few related studies, more 
studies with judicious methodologies are needed to make feasible 
its use in patients refractory to pain and previously submitted to 
conservative treatments.
Keywords: Botulinum toxin type A, Facial pain, Myofascial pain 
syndromes, Temporomandibular joint disorder syndrome.
RESUMO
JUSTIFICATIVA E OBJETIVOS: Disfunção temporoman-
dibular (DTM) abrange um conjunto de alterações craniofaciais, 
que pode envolver a articulação temporomandibular (ATM), os 
músculos da mastigação e/ou estruturas associadas. As DTM mus-
culares são as mais frequentes e um dos seus subtipos compreende 
a dor miofascial. A toxina botulínica tipo A (BoNT A), tem sido 
objeto de estudos no controle da dor, incluindo dor miofascial, e 
está relacionada ao mecanismo de alívio da dor, não somente nos 
receptores da junção neuromuscular. O objetivo deste estudo foi 
acessar os artigos que abordam o uso da BoNT A no tratamento da 
dor miofascial nos músculos da mastigação.
CONTEÚDO: Foi realizada uma busca nas bases de dados 
Pubmed, LILACS e BVS, de 2000 a abril de 2012, cruzando-se 
os descritores: toxinas botulínicas tipo A, síndromes da dor mio-
fascial, dor facial, síndrome da disfunção da articulação temporo-
mandibular, pontos-gatilho, bruxismo, articulação temporoman-
dibular, músculo masseter e músculo temporal. Como critérios 
de inclusão foram analisados estudos randomizados, duplamente 
encobertos ou encobertos, com 10 ou mais participantes, de aspec-
tos metodológicos aleatórios, que relacionassem o uso da toxina 
botulínica na dor miofascial da DTM nos músculos da mastigação, 
mais especificamente masseter e temporal, limitados para o idioma 
inglês encontrando-se seis estudos que foram incluídos neste estudo.
CONCLUSÃO: O uso da BoNT A não se mostrou mais eficiente 
no tratamento da dor miofascial do que os tratamentos convencio-
nais já estabelecidos. Por existirem diversas variáveis não contro-
ladas nos poucos estudos pertinentes, mais estudos, com metodo-
logias criteriosas, são necessários para viabilizar sua aplicação em 
pacientes refratários à dor submetidos previamente a tratamentos 
conservadores.
Descritores: Dor facial, Síndrome da disfunção da articulação 
temporomandibular, Síndromes da dor miofascial, Toxinas botulíni-
cas tipo A. 
INTRODUCTION
Temporomandibular disorders (TMD) involve a set of craniofa-
cial changes with multifactorial or biopsychosocial etiology, which 
may involve the temporomandibular joint (TMJ), masticatory 
muscles and/or musculoskeletal structures associated to head and 
neck. Its primary symptom is pain, but may also present with jaw 
movements limitation and joint noises.
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Whichever the nature of the pain, it brings changes in psychic be-
havior, with increased muscle tone e consequent presence of myo-
fascial pain1. Conversely, long-lasting pain has no biological value 
and may become the major reason for patients’ distress. In addition 
to neurophysiologic phenomena, psychological, cognitive, behav-
ioral and social aspects are also involved1-3.
Muscle pain is transmitted by nervous afferent fibers groups III 
and IV to the central nervous system, which processes noxious 
stimulation quantity, intensity, duration and location. The exces-
sive use of a muscle by repetitive movements leads to traumas which 
generate localized muscle contraction and the release of algoge-
nous substances promoting local pain2-4. This muscle disorder pro-
motes excessive release of acetylcholine and an exacerbated crisis is 
perpetuated within the tight muscle band5.
Muscle TMDs are the most frequent and one of its subtypes is 
myofascial pain, characterized by a state of chronic, regional mus-
culoskeletal pain, with specific signs and symptoms as the presence 
of myofascial trigger points (TP). TPs are hyperirritable nodes 
located in a tight muscle, tendon or fascial band which, when 
palpated, produce local pain and referred pain outside the pain-
ful area6,7. The severity of symptoms caused by TPs varies from 
disabling and severe pain, to movement limitations and postural 
distortion7.
Botulinum toxin type A (BoNT A), currently called Onabotuli-
num toxin A by the Food and Drug Administration (FDA), has 
been studied to control pain, including myofascial pain, and is re-
lated to pain relief mechanisms, not only in neuromuscular junc-
tion receptors, but also in the nociceptive receptors system4,8-12.
Considered lethal for many centuries, its clinical and muscular 
symptoms were described in detail in the early 19th Century by 
the physician Justinus Kerner. However, Clostridium botulinum 
(C. botulinum), microorganism producing botulinum toxin, was 
only identified in 1895 in Belgium by Emile Pierre Marie Van Er-
mengem. BoNT is a neurotoxin produced by different micro-
organisms initially called C. botulinum. Depending on the envi-
ronment where they develop and produce their spores, they affect 
different subsets of live species producing variants13. Its initial 
classification in seven strains, called from A to G, is currently not 
satisfactory, and now C. botulinum is divided in four physiological 
groups together with Clostridium argentinense (C. argentinense), 
and aggregating Clostridium butyricum (C. butyricum) and Clos-
tridium baratii (C. baratii) strains13.
BoNT A action mechanism propositions were suggested in mid 
1950, showing that it blocked acetylcholine (ACh) release from mo-
tor nervous terminations8,12. Once inside the body, the toxin would 
reach neuromuscular junctions where, after its internalization, bind-
ing to its receptor by endocytosis, it may develop the activity of 
blocking nervous impulse transmission for 8 to 16 weeks13,14.
As from the 1980’s, with the use of BoNT A by Alan Scott to cor-
rect strabismus in apes, its clinical application for therapeutic use 
has started15. BoNT A has been used for some neurological, uro-
logical, gastrointestinal and proctologic disorders. It is also widely 
used in Ophthalmology, ENT, Dermatology and Gynecology8,16. 
It is indicated to treat Parkinson’s disease17 and is being widely used 
to manage pain18. Currently, BoNT therapeutic capacity is being 
determined by categorization and genetic engineering to act in 
changing binding sites, in catalysis and duration of the toxin, al-
lowing specific effects and several therapeutic actions such as: in 
SNARE mediation during secreting processes involved with diabe-
tes, in respiratory disorders and even in processes controlling im-
mune and inflammatory disorders19.
There are some restrictions to its use such as: drug allergy, pregnan-
cy, lactation, difficult cooperation of patient (fear of the method), 
infection or inflammation in the proposed injection site, anatomic 
abnormalities making injection difficult or impossible (e.g., obe-
sity or deformities), comorbidities (viral infection, chronic neu-
ropathic pain), patients under anticoagulants or drugs which may 
interfere with muscular transmission, such as aminoglycosides, or 
with neuromuscular joint disorders (severe myasthenia, Lambert-
Eaton syndrome, amyotrophic lateral sclerosis)5,10,20,21. Among ad-
verse effects there are: flu-like symptoms which may last from one 
to two weeks, muscle weakness depending on the injection site. 
This depends on operator’s technique and dose used. There may 
be change in facial expression and difficulties to chew and swallow 
related to masseter muscle injection5,8.
Recent studies were published showing possible antinociceptive 
effects of BoNT A to treat pain not necessarily originated by exces-
sive muscle use9,22. This possible antinociceptive mechanism could 
be explained by the fact that injured cells and primary afferent fi-
bers release a series of chemical mediators, including substance P, 
neurokinin A and calcitonin gene-related peptide (CGRP), which 
have direct effects on the excitability of sympathetic sensory fibers. 
These mediators contribute to create a complex environment re-
sponsible for neurogenic inflammation8,11,23,24.
BoNT A specificity for cholinergic neurons in the presence of 
specific receptors makes it inhibit other neurotransmitters such as 
norepinephrine in motor and neuromediator nerves, including epi-
nephrine, norepinephrine and CGRP, bringing benefits to painful 
symptoms. BoNT A also suppresses the release of substance P, a pep-
tide involved in neurogenic inflammation and pain disorders gen-
esis, and the release of glutamate, another neurotransmitter involved 
with peripheral nociception and spinal cord dorsal horn11,24,25. 
For myofascial pain of masticatory muscles, recommended doses 
in the literature are: masseter (superficial and deep portion) 40-60 
U per injected muscle in two or three sites of superficial masseter 
muscle, taking care with facial nerve motor part, and temporalis 
muscle (anterior, median and posterior portions) 30-50 U per 
muscle, injected in four sites of anterior, median and posterior 
bands of such muscle. Total dose should not exceed 200 U for 
masticatory muscles20.
Because more than 70% of general population have at least one 
TMD symptom, and orofacial patients suffer its resulting clinical 
effects, and due to its physical, psychological and social impact, 
this study aimed at searching articles addressing BoNT to treat 
orofacial pain of masticatory muscles.
CONTENTS 
Literature search strategies
Pubmed, LILACS and BVS databases were queried from 2000 
to April 2012, crossing the following keywords: botulinum toxin 
type A versus myofascial pain versus facial pain versus temporo-
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mandibular joint disorder syndrome, versus trigger-points versus 
bruxism, versus temporomandibular joint versus masseter muscle 
versus temporalis muscle. Inclusion criteria were randomized, 
double blind or blind studies with 10 or more participants, with 
randomized methodological aspects, relating the use of BoNT for 
TMD myofascial pain of masticatory muscles, more specifically 
masseter and temporalis, limited to the English language.
Review articles, clinical reports, open label studies, animal model 
studies, articles not related to TMD myofascial pain, disk displace-
ment, tension headache, migraine and muscle movement disorders 
were excluded. After crossing keywords in all possible manners and 
applying inclusion and exclusion criteria, six studies were included 
and are summarized in table 1.
Description of selected literature
In a crossover randomized double-blind placebo-controlled study, 
the efficacy of BoNT A was analyzed to manage moderate to se-
vere chronic pain in masticatory muscles where 25 U were injected 
in each left and right temporalis muscle and 50 U in each right and 
left masseter muscle in three different sites per muscle26. Data were 
collected every week and were crossed in 16 weeks. Visual analog 
scale (VAS) was used to measure pain intensity as primary variable. 
Secondary variables were: maximum painless mouth opening, 
muscle palpation in 12 points and four general questions. Only 10 
patients have finished the study and there were no statistically sig-
nificant differences between BoNT A and placebo. The study has 
not supported the use of BoNT26.
In a different randomized, blind and placebo-controlled study, pa-
tients received BoNT injection in masticatory muscles: masseter, 
temporalis and medial pterygoid27. All patients had chronic pain 
resulting from masticatory muscles hypermobility and had been 
previously treated with adequate conservative methods from 3 
to 34 months. Pain symptoms were evaluated by VAS before and 
after treatment and the observation period was of three months, 
were 35 U BoNT A in saline, and NaCI solution as placebo were 
administered in temporalis and masseter muscles. Results have 
shown 91% improvement in the BoNT A group and just local 
pain improvement in the placebo group. The conclusion was that 
BoNT A is an innovative and effective method for chronic facial 
pain associated to muscle hyperactivity in patients not responding 
to conventional treatments27.
Another publication was a double-blind, randomized, placebo-
controlled study where patients had bruxism and masticatory mus-
cles myofascial pain28. Treatment protocol was muscular administration of 
four BoNT A (Botox, Allergan Inc., Irivine, CA) in masseter mus-
cles on both sides and in anterior temporalis muscles on both sides, 
in a total of 100 U. Injections were controlled with topography 
and ultrasound. Clinical parameters were evaluated at baseline, 
one week, one month and six months after treatment and included 
pain at rest and during chewing, chewing efficiency, maximum 
mouth opening, protrusion and lateral protrusion, jaw movements 
limitation, subjective efficacy and tolerance to treatment. Results 
have shown improvement with BoNT A of jaw movements ampli-
tude and pain at rest and during chewing. Clinical results variables 
were better with Botox as compared to placebo. Patients treated 
with BoNT A had better perception of treatment efficacy than 
those of the placebo group. Differences were not significant in 
some cases due to the small sample size. Authors have concluded 
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Nixdorf, 
Heo and 
Major26
Von 
Linder 
et al.27
24 weeks
12 weeks
SG = CG
SG > CG                 
Crossover, 
double-blind, 
randomized 
controlled 
study.
Double-blind, 
randomized 
controlled 
study.
n = 90 
individuals;              
refractory to 
conservative 
treatment
PAIN - by VAS
n=15 females;      
age -18 to 
45 years;       
myofascial pain 
according to 
RDC/TMD
PAIN - by VAS;             
maximum mouth 
opening amplitude;   
pain at palpation 
and 4 general 
questions.
SG= 25U m.R tempo-
ral, 25U m. L tempo-
ral, 50U R masseter 
m., 50U L masseter 
m. Doses divided in 
three sites for each 
muscle (=0.2 cm3).             
CG= 0.9% saline. 
Application of 0.2 cm3 
in each of the three 
sites of each muscle.              
Data collection: 
baseline, 8, 16 and 24 
weeks.
SG = 35U in 0.7 mL 
de NaCl injected in 
each side of  temporal, 
masseter and me-
dial pterygoid muscles.      
CG= 0.7 mL of NaCl 
injected in each side 
of temporal, masseter 
and medial pterygoid 
muscles.      
Data collection: baseline 
and 4 weeks. 
Authors Types of Study Samples Evaluated Variables Study 
Duration
Methodology Result*
Table 1 - Articles adressing the use of  BoNT to manage masticatory muscles fascial pain.
 (continua...)
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that BoNT A was effective to decrease myofascial pain symptoms 
in patients with bruxism28.
A randomized study with patients with myofascial pain and TP-
associated headache has used lidocaine and dry-needling in the 
referred TP29. Patients were divided in three groups: G1 dry-nee-
dling, G2 0.25% lidocaine without vasoconstrictor and G3 25 U 
or 50 U of BoNT. The following parameters were evaluated during 
12 weeks: pain intensity levels, frequency, duration and sensi-
tivity after injection, length of relief and use of rescue analgesics. 
All groups had favorable results for evaluated requisites, except for 
the use of rescue medication and sensitivity after injection, which 
was better for G3. Authors have concluded that, considering its 
low cost, lidocaine could be adopted as the substance of choice and 
BoNT would be reserved for refractory cases where expected ef-
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RDC/TMD = Research Diagnostic Criteria for Temporomandibular Disorder; VAS = visual analog scale; IHS = International Headache Society; IMMPACT = 
Initiative on Methods, Measurement and Pain Assesssment in Clinical Trials; SG = Study Group; CG = Control Group.     
       *Evaluated result was with regard to pain and movement amplitude improvement.
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Guarda-
Nardini 
et al.28
Venâncio, 
Alencar and 
Zamperini29
Ernberg 
et al.30
Guarda-
Nardini 
et al.14
24 weeks
12 weeks
26 weeks
12 weeks
SG > CG                 
SG = CG
SG = CG
SG1 = SG2 = CG
Double-blind, 
randomized 
controlled 
study.
Randomized 
controlled 
study.
Crossover, 
double-blind, 
randomized 
controlled 
study.
Double-blind, 
randomized 
controlled 
study.
n = 45 individuals;     
(40 females and 
5 males) age - 
18 to 65 years;         
headache according 
to IHS induced by 
trigger-points in 
masseter and tem-
poral muscles.   
n = 21 individuals;             
(19 females and 2 
males)  mean 
age - 38 years;                
myofascial pain 
according to 
RDC/TMD; 
refractory to 
conservative 
treatment      
n = 30 individuals;             
(22 females and 8 
males) age - 23 
to 69 years;                 
myofascial pain 
according to RDC/
TMD; refractory to 
conservative 
treatment         
Modified symptoms 
severity 
index (SSI);                      
trigger points 
palpation; 
pain diary and                           
pain questionnaire.
Use of IMMPACT;        
use of analgesics;     
painless mouth 
opening amplitude; 
apin at palpation;      
pressure pain 
threshold and 
tolerability.
PAIN - by 
VAS and                          
maximum 
mouth opening 
amplitude.
n=20 in-
dividuals;                          
(10 females 
and 10 males)     
age - 25 to 
45 years;                 
myofascial pain 
according to 
RDC/TMD   
PAIN - by VAS;             
maximum mouth 
opening amplitude;    
mastictory 
efficiency - 
by VAS and                     
efficacy and 
tolerabilityto 
treatment.
SG = 20U R temporal 
m., 20U L temporal 
m., 30U R masseter 
m, 30U L masseter m. 
Doses divided in three 
temporal m. sites and 
4 masseter m. sites.              
CG= 0.9% saline. 
Application in each 
site corresponding to 
SG in each muscle.                     
Data collection: base-
line,1, 4 and 24 weeks.
SG1 = 0.2 mL of 25%  
lidocaine without 
vasoconstrictor in 1 
to 3 trigger points.                   
SG2= 25U or 50 U 
BoNT in 1 to 3 
trigger points. 
CG = Dry needling in 1 
to 3 trigger points. 
Data collection: base-
line, 10 min after, 1,4 
and 12 weeks.
SG = 100U in 1.0 mL 
of 9% saline, 0.1 mL 
deep part, 0.2 mL 
fixed insertion and 0.2 
mL mobile insertion of 
each L and R masseter.    
CG=1.0 mL of 0.9% 
saline. 0.1 mL deep 
part, 0.2 mL fixed 
insertion and 0.2 mL 
mobile insertion of 
each R and L masseter.    
Data collection: base-
line,  4,12,14,18 and 
26 weeks.                                
SG = 150U in each side 
of masseter and temporal 
muscles by the Manfredini 
et al.31 technique CG 
= Fascial manipulation.            
Data collection: baseline 
and 12 weeks.                                    
(...continuation)
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fects of other therapies could not be reached29.
Another crossover randomized double-blind and placebo-con-
trolled study has evaluated the effect of BoNT A on persistent 
muscle TMD pain30. Patients had TMD without adequate pain 
relief after conventional treatment and received BoNT injection; 
the control group received isotonic saline solution. Both drugs 
were randomly injected in three standardized sites of the mas-
seter muscle on both sides. Patients were followed after one and 
three months. After this period, the following parameters were 
evaluated: pain, physical function, emotional function, overall 
improvement and side-effects, in addition to the need for analge-
sics, mouth opening limitation, pain at palpation of masticatory 
muscles on 20 sites, pressure pain threshold and tolerance to pain. 
There has been significant pain improvement (30%) one month 
after BoNT injection, but this was not true for saline solution in-
jection, as shown by other studies. The conclusion was that this 
improvement is regardless of its muscle relaxation effects, because 
the relief may precede this relaxation, being also present outside 
the areas of BoNT injection. There has been no primary difference 
between drugs, and results have not shown a relevant clinical effect 
of BoNT A to treat persistent TMD myofascial pain or to bring 
about emotional changes30.
A randomized controlled study has compared the effectiveness of 
BoNT and the treatment with fascial manipulation of masseter 
and bilateral temporal muscles14. All patients had myofascial pain 
and were distributed in Group A receiving BoNT in a single ses-
sion and Group B receiving multiple muscle fascia manipulation 
sessions. Evaluated parameters were maximum pain level by VAS, 
maximum mouth opening, right and left protrusion and laterality 
in the beginning, at the end and one month later. Follow up time 
was three months. There has been pain improvement in both cases 
and BoNT was better with regard to jaw movement amplitude14.
Refractory patients are common in chronic diseases. Accurate 
myofascial pain diagnosis is difficult because its symptoms may be 
mistaken for other diseases, and basically depends on history and 
palpation exams, in addition to well trained professionals. BoNT 
is used to treat pain induced by spasm and dystonia because it para-
lyzes the overloaded muscle, but it is known that its analgesic effect 
is not only related to muscle relaxation and may be independent of 
it. So, hypothetically, BoNT A could be used to relieve myofascial 
pain due to its antinociceptive properties. 
However, current studies still have several uncontrolled variables 
such as: small sample size, waiver of patients during the study, use 
of rescue drugs, differences in injection sites and doses used, which 
make these studies not reproducible. It is also necessary to investi-
gate which would be its therapeutic benefits for these disorders, in 
addition to considering time between injections, the formation of 
antibodies and the complications of its use.
CONCLUSION 
BoNT A was not more effective to treat myofascial pain than al-
ready established conventional treatments because there are few 
randomized, double-blind or placebo-controlled studies, which 
brings lots of controversies about its effectiveness. Further 
studies are needed to enhance the understanding of long-lasting 
pain pathophysiology and the mechanisms through which BoNT 
may change pain, in addition to the feasibility of its application in 
refractory myofascial pain patients, simultaneously with physical 
therapies.
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